Protagenic Therapeutics Inc
PTIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$982.94K
Close$
$-0.49
197.5% downside
Current Fair Value
197.5% downsideOvervalued by 197.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $982,943.00 |
|---|---|
| Enterprise Value | $1.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.45 |
| Beta | 0.47 |
| Outstanding Shares | 1,934,878 |
Return
| Return on Equity | 109.90% |
|---|---|
| Return on Assets | -241.84% |
| Return on Invested Capital | 177.04% |
Valuation & Multiples
| P/E Ratio | -0.2 |
|---|---|
| PEG | 0.08 |
| Price to Sales | - |
| Price to Book Ratio | -0.17 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.23 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.64 |
| Debt to Equity | -0.67 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-4.48
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.46%▼ 2.56% |
|---|---|
| Total Invested | $44,387▼ 70.59% |
| Investors Holding | 4▼ 7.00% |
ESG Score
No data
About Protagenic Therapeutics Inc
1 employeesProtagenic Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of novel and naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorder...